Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers
This double-blind, placebo-controlled, cross-over study (n=20) found that psilocybin (18.2mg/70kg) disrupted certain auditory-related brain signals (P300, not MMN) which decreased in amplitude in correlation with higher psilocin serum levels (and more intense psychedelic experiences).
Authors
- Tomáš Páleníček
- František Tylš
- Martin Brunovský
Published
Abstract
Rationale
Disruption of auditory event-related evoked potentials (ERPs) P300 and mismatch negativity (MMN), electrophysiological markers of attentive and pre-attentive cognitive processing, is repeatedly described in psychosis and schizophrenia. Similar findings were observed in a glutamatergic model of psychosis, but the role of serotonergic 5-HT2A receptors in information processing is less clear.
Objectives
We studied ERPs in a serotonergic model of psychosis, induced by psilocybin, a psychedelic with 5-HT2A/C agonistic properties, in healthy volunteers.
Methods
Twenty subjects (10M/10F) were given 0.26 mg/kg of psilocybin orally in a placebo-controlled, double-blind, cross-over design. ERPs (P300, MMN) were registered during the peak of intoxication. Correlations between measured electrophysiological variables and psilocin serum levels and neuropsychological effects were also analyzed.
Results
Psilocybin induced robust psychedelic effects and psychotic-like symptoms, decreased P300 amplitude (p = 0.009) but did not affect the MMN. Psilocybin’s disruptive effect on P300 correlated with the intensity of the psychedelic state, which was dependent on the psilocin serum levels. We also observed a decrease in N100 amplitude (p = 0.039) in the P300 paradigm and a negative correlation between P300 and MMN amplitude (p = 0.014).
Conclusions
Even though pre-attentive cognition (MMN) was not affected, processing at the early perceptual level (N100) and in higher-order cognition (P300) was significantly disrupted by psilocybin. Our results have implications for the role of 5-HT2A receptors in altered information processing in psychosis and schizophrenia.
Research Summary of 'Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers'
Introduction
Bravermanová and colleagues frame the study around well-documented electrophysiological abnormalities in schizophrenia and psychosis, notably reductions in early and late auditory event-related potentials (ERPs). Early ERP components such as P50 and N100 index sensory-related processing, whereas mismatch negativity (MMN) and P300 index pre-attentive and attentive information processing respectively. MMN and P300 deficits are robust findings in chronic schizophrenia and have been proposed as neurophysiological endophenotypes, but the receptor mechanisms that produce these ERP changes are not fully understood. To investigate the contribution of serotonergic 5-HT2A/C receptor agonism to these ERP alterations, the investigators tested ERPs during acute psilocybin intoxication in healthy volunteers. They aimed to measure both MMN and P300 within the same session to determine whether psilocybin disrupts pre-attentive processing (MMN), attentive/higher-order processing (P300), or both, and whether such effects are related to psilocin serum levels and the intensity of subjective psychedelic effects. Their a priori hypotheses were that psilocybin would decrease P300 amplitude, reduce MMN at later intoxication stages, and show relationships with plasma psilocin and psychometric measures.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Bravermanová, A., Viktorinová, M., Tylš, F., Novák, T., Androvičová, R., Korčák, J., Horáček, J., Balíková, M., Griškova-Bulanova, I., Danielová, D., Vlček, P., Mohr, P., Brunovský, M., Koudelka, V., & Páleníček, T. (2018). Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers. Psychopharmacology, 235(2), 491-503. https://doi.org/10.1007/s00213-017-4807-2
References (22)
Papers cited by this study that are also in Blossom
Carhart-Harris, R. L., Leech, R., Erritzoe, D. et al. · Schizophrenia Bulletin (2012)
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Carter, O., Burr, D. C., Pettigrew, J. D. et al. · Journal of Cognitive Neuroscience (2006)
Frohlich, J, Van Horn, J. D. · Journal of Psychopharmacology (2013)
Geyer, M. A., Vollenweider, F. X. · Trends in Pharmacological Sciences (2008)
Gouzoulis-Mayfrank, E., Schreckenberger, M., Sabri, O. et al. · Neuropsychopharmacology (1999)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Hasler, F., Grimberg, U., Benz, M. A. et al. · Psychopharmacology (2004)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Show all 22 referencesShow fewer
Kometer, M., Schmidt, A., Bachmann, R. et al. · Biological Psychiatry (2012)
Kraehenmann, R., Preller, K. H., Scheidegger, M. et al. · Biological Psychiatry (2015)
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)
Nichols, D. E. · Pharmacological Reviews (2016)
Quednow, B. B., Kometer, M., Geyer, M. A. et al. · Neuropsychopharmacology (2011)
Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H. et al. · JAMA Psychiatry (1994)
Timmermann, C., Spriggs, M. J., Kaelen, M. et al. · Neuropharmacology (2018)
Tylš, F., Páleníček, T., Horacek, J. · European Neuropsychopharmacology (2013)
Tylš, F., Páleníček, T., Kadeřábek, L. et al. · Behavioural Pharmacology (2016)
Umbricht, A., Schmid, L., Koller, R. · JAMA Psychiatry (2000)
Umbricht, A., Vollenweider, F. X., Schmid, L. et al. · Neuropsychopharmacology (2003)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Cited By (12)
Papers in Blossom that reference this study
Vejmola, C., Šíchová, K., Syrová, K. et al. · Biological Psychiatry (2025)
Suay, D., Aicher, H. D., Kometer, M. et al. · NeuroImage (2025)
Haggarty, C. J., Molla, H. M., Glazer, J. et al. · Psychedelic Medicine (2024)
Casanova, A. F., Ort, A., Smallridge, J. W. et al. · iScience (2024)
Erritzoe, D., Timmermann, C., Godfrey, K. et al. · Nature Mental Health (2024)
Nikolič, M., Viktorin, V., Zach, P. et al. · European Neuropsychopharmacology (2023)
Prugger, J., Derdiyok, E., Dinkelacker, J. et al. · Scientific Data (2022)
Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)
Perry, C. M., Malina, M. · Psychopharmacology (2021)
Duerler, P., Brem, S., Fraga-González, G. et al. · Cerebral Cortex (2021)
Show all 12 papersShow fewer
Dudysová, D., Janků, K., Šmotek, M. et al. · Frontiers in Pharmacology (2020)
Smigielski, L., Kometer, M., Scheidegger, M. et al. · Human Brain Mapping (2020)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.